Search Within

Andriy Derkach

Formats
  1. Meeting Abstract (104)
  2. Journal Article (56)
  3. Research Letter (11)
  4. Correspondence (3)
Groups
  1. Biostatistics Service (174)
  2. Epidemiology and Biostatistics (174)
  3. Population Sciences Research Program (174)
  4. Department of Medicine (160)
  5. Hematologic Malignancies, Division of (159)
  6. Center for Hematologic Malignancies (153)

More Groups

People
  1. Urvi Shah (80)
  2. Malin Hultcrantz (79)
  3. Alexander Lesokhin (78)
  4. Carlyn Rose Tan (71)
  5. Sham Mailankody (71)
  6. Hani Hassoun (70)

More People

Years
  1. 2025 (10)
  2. 2024 (47)
  3. 2023 (44)
  4. 2022 (35)
  5. 2021 (22)
  6. 2020 (16)
Publications
  1. Blood (75)
  2. Clinical Lymphoma, Myeloma and Leukemia (21)
  3. Journal of Clinical Oncology (14)
  4. Blood Advances (10)
  5. Leukemia and Lymphoma (6)
  6. Blood Cancer Journal (5)

More Publications

Publishers
  1. American Society of Hematology (85)
  2. Elsevier Inc. (24)
  3. American Society of Clinical Oncology (14)
  4. Nature Publishing Group (12)
  5. American Association for Cancer Research (8)
  6. Taylor & Francis Group (6)

More Publishers

Results (174)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Long-term sustained minimal residual disease (MRD) negativity in patients with multiple myeloma treated with continuous lenalidomide maintenance therapy: A clinical and correlative phase 2 study
    Meeting Abstract

    Diamond, B.; Korde, N.; Lesokhin, A. M.; Smith, E. L.; Shah, U. A.; Mailankody, S.; Hultcrantz, M.; Hassoun, H.; Lu, S. X.; Tan, C.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • Chemotherapy and COVID-19 outcomes in patients with cancer
    Journal Article

    Jee, J.; Foote, M. B.; Lumish, M.; Stonestrom, A. J.; Wills, B.; Narendra, V.; Avutu, V.; Murciano-Goroff, Y. R.; Chan, J. E.; Derkach, A.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Hypofibrinogenemia and disseminated intravascular coagulation rarely complicate treatment-naìˆve acute lymphoblastic leukemia
    Correspondence

    Gaulin, C.; Chan, A.; Derkach, A.; Park, J. H.; Mantha, S.; Geyer, M. B.; Tallman, M. S.
    Leukemia and Lymphoma (2020)

    Fulltext@MSK | Save
  • Venetoclax and hypomethylating agents (HMAs) induce high response rates in MDS, including patients after HMA therapy failure
    Journal Article

    Ball, B. J.; Famulare, C. A.; Stein, E. M.; Tallman, M. S.; Derkach, A.; Roshal, M.; Gill, S. I.; Manning, B. M.; Koprivnikar, J.; McCloskey, J.; more...
    Blood Advances (2020)

    Fulltext@MSK | Save